Trump to announce new drug-pricing deals later today

By Jaimy Lee The White House has already made deals with five drugmakers to lower the prices of certain medications like Wegovy and Xeljanz On Nov. 6, President Donald Trump spoke at a White House event focused on lowering the prices of drugs, including some GLP-1s, marketed by Eli Lilly and Novo Nordisk. More deals with drugmakers are set to be announced. The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. Karoline Leavitt, the White House press secretary, wrote on X that the deals will be made public on Friday at 1 p.m. Eastern time. She did not disclose which companies are involved in this announcement. Reuters has reported that AbbVie (ABBV) is one of about five companies involved in Friday's announcement, citing sources familiar with the matter. Bristol Myers Squibb (BMY), Gilead (GILD) and ?Merck (MRK) also will be involved in the announcement, according to Reuters. A handful of drugmakers have already disclosed pricing deals with the Trump administration and plan to sell certain drugs at a discount on TrumpRx, the White House's new direct-to-consumer website that's expected to launch early next year. In exchange, the companies will get relief from tariffs for several years. Back in September, Pfizer (PFE) was the first drug company to strike a deal with the administration. Then came AstraZeneca (AZN), EMD Serono (the U.S. and Canadian arm of Merck KGaA (XE:MRK)), Eli Lilly (LLY) and Novo Nordisk (NVO). Amgen (AMGN) said in October that its direct-pay site will be available via TrumpRx. Most of the medications included so far treat everyday conditions like atopic dermatitis, migraine, obesity and fertility. No deals for cancer drugs or treatments for rare diseases have been disclosed. It's unclear who will use TrumpRx to directly buy their medications, and that has led to questions about how much of an impact the pricing deals will have on patients. But the deals have helped establish certainty regarding tariffs and pricing, reducing a key overhang for investors. "With our landmark voluntary agreement with the U.S. government, we now have greater clarity on two critical fronts: pricing in the U.S. and tariffs," Pfizer CEO Albert Bourla told investors earlier this week. Victor Reklaitis contributed. -Jaimy Lee This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-19-25 1045ET